Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodesix, Inc. filings document the public reporting of a Nasdaq-listed diagnostics company with common stock trading under BDSX. The company’s 8-K reports disclose operating and financial results for its Diagnostic Testing and Development Services activities, including revenue trends, gross margin, guidance, and related press-release exhibits.
Proxy materials cover annual meeting proposals, board and governance matters, and stockholder voting. Other material-event filings document capital-structure and security-holder matters, including the completed one-for-twenty reverse stock split, common stock listing details, Nasdaq minimum bid price compliance, and amendments to the company’s charter.
Biodesix, Inc. is registering up to 375,000 shares of common stock for resale by Perceptive Credit Holdings IV, LP. This prospectus registers resale rights for shares issuable upon exercise of warrant certificates granted under multiple amendments to a credit agreement. The Company will not receive proceeds from resale; any cash exercise proceeds would be received by the Company. The filing discloses a Beneficial Ownership Limitation that prevents Perceptive from exercising warrants if post-exercise ownership would exceed 9.99%. The prospectus lists 10,355,809 shares outstanding as of May 20, 2026 and states the Nasdaq last sale price was $14.37 on May 20, 2026.
Biodesix, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected two Class III directors to serve until the 2029 annual meeting, approved on a non-binding advisory basis the compensation of named executive officers, and chose to hold say-on-pay votes every year.
They also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. A total of 10,107,219 shares of common stock were entitled to vote as of the March 23, 2026 record date.
Perceptive Advisors and related entities report beneficial ownership of common stock of Biodesix, Inc. The group holds 483,694 shares, representing 4.6% of outstanding common stock based on April 29, 2026 share data. The Credit Fund directly holds 56,866 shares and 375,000 warrants; the Opportunity Fund directly holds 51,828 shares. The filing states the Warrants are currently exercisable subject to a 9.99% ownership limitation. Shared voting and dispositive power is reported at 483,694 shares for Perceptive Advisors, Perceptive Credit, and Joseph Edelman.
Biodesix, Inc. ownership update: Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of 416,599 shares of Biodesix common stock, representing 4.1% of the class. The percentage is calculated using 10,108,580 shares outstanding as of April 29, 2026, per the Issuer's Form 10-Q cover.
The filing is an Amendment No. 1 to a Schedule 13G/A and clarifies the ownership structure across Soleus Capital entities and Guy Levy, who disclaims beneficial ownership except for Section 13(d) purposes.
Biodesix, Inc. reported strong top-line growth for the quarter ended March 31, 2026, with revenue rising to $25.6 million from $18.0 million a year earlier, driven by both lung diagnostic tests and development services. Operating loss narrowed to $6.2 million, and net loss improved to $7.8 million from $11.1 million, as higher revenue offset increased sales, marketing, and R&D expenses.
Cash and cash equivalents increased to $25.6 million from $19.1 million at the prior year-end, helped by an at-the-market equity raise of about $17.2 million in gross proceeds. Total assets reached $94.6 million, and stockholders’ equity turned positive at $9.1 million versus a prior deficit, partly reflecting new capital and warrant-related equity. Biodesix also extended its $50.0 million Perceptive term loan maturity to November 2028, keeping an interest-only structure but issuing additional equity warrants as consideration.
Biodesix, Inc. reported strong first quarter 2026 results with total revenue of $25.6 million, up 42% year over year, driven by growth in both Diagnostic Testing and Development Services. Diagnostic Testing revenue reached $22.3 million on 29% higher test volumes and better average revenue per test, while Development Services revenue nearly doubled to $3.3 million.
Gross margin was 84% in the quarter, or 82% excluding a one‑time $0.4 million tax recovery, about a 300‑basis‑point improvement from a year earlier. Operating expenses rose 18% to $27.6 million as the company invested in sales, marketing, and G&A, including $1.1 million of share-based compensation. Net loss improved to $7.8 million from $11.1 million, and Adjusted EBITDA loss narrowed to $4.1 million from $6.2 million.
Cash and cash equivalents increased to $25.6 million from $19.0 million at year end, helped by $16.8 million of at-the-market net proceeds. Reflecting the strong start to the year, Biodesix raised its 2026 total revenue outlook to $108–114 million, with the midpoint implying about 25% growth over 2025, and continues to target progress toward Adjusted EBITDA profitability.
Biodesix, Inc. (Common Stock) has a Schedule 13G filed showing AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman beneficially own 758,328 shares, representing 7.7% of the outstanding common stock as of 03/31/2026. The filing states the Reporting Persons have sole voting and sole dispositive power over these shares.
Biodesix, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on May 19, 2026 at 1:00 p.m. Mountain Time. Stockholders of record on March 23, 2026, when 10,107,219 common shares were outstanding, may vote online on four key proposals.
These proposals are the election of two Class III directors to serve until 2029, a non-binding advisory vote on 2025 compensation for named executive officers, an advisory vote on how often to hold future say‑on‑pay votes (the board recommends every one year), and ratification of KPMG LLP as independent auditor for 2026.
The proxy also outlines Biodesix’s board structure, committee membership, director and executive pay (including 2025 salary increases, cash bonuses and equity awards) and new severance and change‑in‑control agreements for senior executives, together with stock ownership, equity plan data and pay‑versus‑performance disclosures.
Biodesix Inc. chairman John Patience exercised restricted stock units into common shares on March 31, 2026. He converted 1,361 RSUs into 1,361 shares of common stock at an exercise price of $0.00 per share. Following the transactions, he directly holds 24,022 common shares and 4,082 RSUs, with additional indirect holdings through Patience Enterprises LP, the John Patience Living Trust, and his spouse.